Travere Therapeutics (TVTX) Current Assets (2012 - 2026)

Travere Therapeutics' Current Assets history runs 15 years deep, the most recent figure standing at $392.7 million for Q1 2026.

• Quarterly Current Assets rose 4.95% year-over-year to $392.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $392.7 million (up 4.95% YoY) and the FY2025 annual result came in at $437.6 million, up 5.01% from the prior year.
• Current Assets was $392.7 million for Q1 2026 at Travere Therapeutics, down from $437.6 million in the prior quarter.
• Across five years, Current Assets topped out at $686.2 million in Q3 2023 and bottomed at $324.7 million in Q3 2024.
• A 5-year average of $484.5 million and a median of $481.1 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets climbed 28.31% — and 2024, when it sank 52.68%.
• Travere Therapeutics' Current Assets stood at $486.4 million in 2022, then advanced by 26.79% to $616.8 million in 2023, then slumped by 32.44% to $416.7 million in 2024, then climbed by 5.01% to $437.6 million in 2025, then slipped by 10.26% to $392.7 million in 2026.
• Business Quant data shows TVTX's Current Assets at $392.7 million in Q1 2026, $437.6 million in Q4 2025, and $371.1 million in Q3 2025.